142 related articles for article (PubMed ID: 32583656)
21. Efficacy of quinagolide in resistance to dopamine agonists: results of a multicenter study. Club de l'Hypophyse.
Rohmer V; Freneau E; Morange I; Simonetta C
Ann Endocrinol (Paris); 2000 Nov; 61(5):411-7. PubMed ID: 11084391
[TBL] [Abstract][Full Text] [Related]
22. Chiasmal herniation as a complication of bromocriptine therapy.
Taxel P; Waitzman DM; Harrington JF; Fagan RH; Rothfield NF; Chen HH; Malchoff CD
J Neuroophthalmol; 1996 Dec; 16(4):252-7. PubMed ID: 8956160
[TBL] [Abstract][Full Text] [Related]
23. Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI).
Manuchehri AM; Sathyapalan T; Lowry M; Turnbull LW; Rowland-Hill C; Atkin SL
Pituitary; 2007; 10(3):261-6. PubMed ID: 17557207
[TBL] [Abstract][Full Text] [Related]
24. Treatment of macroprolactinoma with cabergoline: a study of 85 patients.
Ferrari CI; Abs R; Bevan JS; Brabant G; Ciccarelli E; Motta T; Mucci M; Muratori M; Musatti L; Verbessem G; Scanlon MF
Clin Endocrinol (Oxf); 1997 Apr; 46(4):409-13. PubMed ID: 9196602
[TBL] [Abstract][Full Text] [Related]
25. Primary medical therapy of micro- and macroprolactinomas in men.
Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
[TBL] [Abstract][Full Text] [Related]
26. Optimal effective doses of cabergoline and bromocriptine and valvular leasions in men with prolactinomas.
Yarman S; Kurtulmus N; Bilge A
Neuro Endocrinol Lett; 2012; 33(3):340-6. PubMed ID: 22635095
[TBL] [Abstract][Full Text] [Related]
27. Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy.
Delgrange E; Duprez T; Maiter D
Clin Endocrinol (Oxf); 2006 Apr; 64(4):456-62. PubMed ID: 16584520
[TBL] [Abstract][Full Text] [Related]
28. Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion.
Wu ZB; Su ZP; Wu JS; Zheng WM; Zhuge QC; Zhong M
Pituitary; 2008; 11(1):63-70. PubMed ID: 17917811
[TBL] [Abstract][Full Text] [Related]
29. Giant cabergoline-resistant prolactinoma in a man who presented with a psychotic episode during treatment: a case report.
Casulari LA; de Castro LF; Kessler IM; Mendonça JL; de Fátima Magalhães Gonzaga M
J Med Case Rep; 2019 Jun; 13(1):183. PubMed ID: 31202268
[TBL] [Abstract][Full Text] [Related]
30. Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists.
Kars M; Pereira AM; Smit JW; Romijn JA
Eur J Intern Med; 2009 Jul; 20(4):387-93. PubMed ID: 19524180
[TBL] [Abstract][Full Text] [Related]
31. Long-term outcome of macroprolactinomas.
Képénékian L; Cebula H; Castinetti F; Graillon T; Brue T; Goichot B
Ann Endocrinol (Paris); 2016 Dec; 77(6):641-648. PubMed ID: 27641080
[TBL] [Abstract][Full Text] [Related]
32. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S
Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
[TBL] [Abstract][Full Text] [Related]
33. First-line surgery in prolactinomas: lessons from a long-term follow-up study in a tertiary referral center.
Andereggen L; Frey J; Andres RH; Luedi MM; El-Koussy M; Widmer HR; Beck J; Mariani L; Seiler RW; Christ E
J Endocrinol Invest; 2021 Dec; 44(12):2621-2633. PubMed ID: 33847973
[TBL] [Abstract][Full Text] [Related]
34. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
Glaser B; Nesher Y; Barziliai S
J Reprod Med; 1994 Jun; 39(6):449-54. PubMed ID: 7932398
[TBL] [Abstract][Full Text] [Related]
35. [A clinical analysis of 103 male patients with macroprolactinoma].
Xu J; Jin ZM; Deng JY; Wu QY; Shi YF
Zhonghua Nei Ke Za Zhi; 2005 May; 44(5):356-9. PubMed ID: 16009006
[TBL] [Abstract][Full Text] [Related]
36. Acute complications of dopamine agonist treatment for macroprolactinoma - how uncommon?
Nadesapillai S; Balcere I; Kaye AH; Tress BM; Colman PG
J Clin Neurosci; 2004 Nov; 11(8):825-8. PubMed ID: 15519856
[TBL] [Abstract][Full Text] [Related]
37. [Treatment of macroprolactinomas with quinagolide (Norprolac)].
Tabarin A; Catargi B
Ann Endocrinol (Paris); 1997; 58(2):87-94. PubMed ID: 9239226
[TBL] [Abstract][Full Text] [Related]
38. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients.
Colao A; Di Sarno A; Landi ML; Scavuzzo F; Cappabianca P; Pivonello R; Volpe R; Di Salle F; Cirillo S; Annunziato L; Lombardi G
J Clin Endocrinol Metab; 2000 Jun; 85(6):2247-52. PubMed ID: 10852458
[TBL] [Abstract][Full Text] [Related]
39. Is a stable or decreasing prolactin level in a patient with prolactinoma a surrogate marker for lack of tumor growth?
Alkabbani AG; Mon SY; Hatipoglu B; Kennedy L; Faiman C; Weil RJ; Hamrahian AH
Pituitary; 2014 Apr; 17(2):97-102. PubMed ID: 23468127
[TBL] [Abstract][Full Text] [Related]
40. Determining Ideal Management for Patients With Coexisting Prolactinomas and Psychiatric Symptoms: A Systematic Review.
Paracha A; Durrani U; Vasireddy S; Abid A; Waheed F; Thomure M
J Psychiatr Pract; 2024 May; 30(3):200-211. PubMed ID: 38819244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
